Overview

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

Status:
Completed

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.

Phase:

Phase 2

Details

Lead Sponsor:

SkyePharma AG

Treatments:

Fluticasone
Formoterol Fumarate
Xhance